Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) FCF Margin (2016 - 2026)

Anika Therapeutics has reported FCF Margin over the past 17 years, most recently at 16.55% for Q1 2026.

  • Quarterly FCF Margin fell 1414.0% to 16.55% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 5.38% through Mar 2026, up 121.0% year-over-year, with the annual reading at 9.33% for FY2025, 535.0% up from the prior year.
  • FCF Margin was 16.55% for Q1 2026 at Anika Therapeutics, down from 13.09% in the prior quarter.
  • Over five years, FCF Margin peaked at 39.99% in Q3 2025 and troughed at 221.11% in Q4 2023.
  • The 5-year median for FCF Margin is 2.58% (2024), against an average of 23.62%.
  • Year-over-year, FCF Margin crashed -20430bps in 2022 and then soared 24519bps in 2024.
  • A 5-year view of FCF Margin shows it stood at 191.25% in 2022, then fell by -16bps to 221.11% in 2023, then surged by 111bps to 24.08% in 2024, then plummeted by -46bps to 13.09% in 2025, then plummeted by -226bps to 16.55% in 2026.
  • Per Business Quant, the three most recent readings for ANIK's FCF Margin are 16.55% (Q1 2026), 13.09% (Q4 2025), and 39.99% (Q3 2025).